Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools.

Lamberth K, Reedtz-Runge SL, Simon J, Klementyeva K, Pandey GS, Padkjær SB, Pascal V, León IR, Gudme CN, Buus S, Sauna ZE.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaag1286. doi: 10.1126/scitranslmed.aag1286.

PMID:
28077675
2.

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.

Mahlangu JN, Weldingh KN, Lentz SR, Kaicker S, Karim FA, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knobe K; adept™2 Investigators.

J Thromb Haemost. 2015 Nov;13(11):1989-98. doi: 10.1111/jth.13141. Epub 2015 Oct 13.

3.

Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.

Doshi BS, Gangadharan B, Doering CB, Meeks SL.

PLoS One. 2012;7(10):e48172. doi: 10.1371/journal.pone.0048172. Epub 2012 Oct 29.

4.

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia.

Mahlangu JN, Coetzee MJ, Laffan M, Windyga J, Yee TT, Schroeder J, Haaning J, Siegel JE, Lemm G.

J Thromb Haemost. 2012 May;10(5):773-80. doi: 10.1111/j.1538-7836.2012.04667.x.

5.

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.

Lentz SR, Ehrenforth S, Karim FA, Matsushita T, Weldingh KN, Windyga J, Mahlangu JN; adept™2 investigators.

J Thromb Haemost. 2014 Aug;12(8):1244-53. doi: 10.1111/jth.12634. Epub 2014 Jul 16.

6.

Thrombelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor.

Pivalizza EG, Escobar MA.

Anesth Analg. 2008 Aug;107(2):398-401. doi: 10.1213/ane.0b013e31817b7864.

PMID:
18633014
8.

Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.

Keshava S, Sundaram J, Rajulapati A, Pendurthi UR, Rao LV.

J Thromb Haemost. 2016 Mar;14(3):546-50. doi: 10.1111/jth.13244. Epub 2016 Feb 15.

9.

40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.

Ljung R, Karim FA, Saxena K, Suzuki T, Arkhammar P, Rosholm A, Giangrande P; Pioneer™1 Investigators.

J Thromb Haemost. 2013 Jul;11(7):1260-8. doi: 10.1111/jth.12237.

10.

Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.

Abshire T, Kenet G.

Haemophilia. 2008 Sep;14(5):898-902. doi: 10.1111/j.1365-2516.2008.01829.x. Epub 2008 Aug 4. Review.

PMID:
18684126
11.

The promise and challenges of bioengineered recombinant clotting factors.

Pipe SW.

J Thromb Haemost. 2005 Aug;3(8):1692-701. Review.

12.

Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.

Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA.

Thromb Haemost. 1998 Nov;80(5):773-8.

PMID:
9843170
13.

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.

Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E.

Thromb Haemost. 1998 Dec;80(6):912-8.

PMID:
9869160
14.

Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A.

Gangadharan B, Delignat S, Ollivier V, Gupta N, Mackman N, Kaveri SV, Lacroix-Desmazes S.

J Thromb Haemost. 2014 Dec;12(12):2065-9. doi: 10.1111/jth.12740. Epub 2014 Oct 25.

15.

Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report.

Kubisz P, Plamenová I, Stasko J, Dobrotová M, Hollý P.

Thromb Haemost. 2010 Apr;103(4):868-70. doi: 10.1160/TH09-10-0709. Epub 2010 Feb 2. No abstract available.

PMID:
20135075
16.

Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.

Qi X, Zhao Y, Li K, Fan L, Hua B.

Blood Coagul Fibrinolysis. 2014 Oct;25(7):754-60. doi: 10.1097/MBC.0000000000000137.

PMID:
24806320
17.

Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.

Hedner U.

Thromb Haemost. 1999 Aug;82(2):531-9. Review. No abstract available.

PMID:
10605747
18.

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.

Jankowski W, McGill J, Lagassé HAD, Surov S, Bembridge G, Bunce C, Cloake E, Fogg MH, Jankowska KI, Khan A, Marcotrigiano J, Ovanesov MV, Sauna ZE.

Blood Adv. 2019 Sep 10;3(17):2668-2678. doi: 10.1182/bloodadvances.2019000338.

19.

Toward optimal therapy for inhibitors in hemophilia.

Kempton CL, Meeks SL.

Blood. 2014 Nov 27;124(23):3365-72. doi: 10.1182/blood-2014-05-577643. Review.

PMID:
25428222
20.

Supplemental Content

Support Center